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gradingAbstract Aim of the work: To correlate between synovial vascular endothelial growth factor
(VEGF), clinical, functional and radiological ﬁndings in knee osteoarthritis (KOA) patients.
Patients and methods: Twenty patients with primary KOA were clinically examined and the
modiﬁed Ritchie articular index (RAI) recorded. The knees were examined and knee pain evaluated
by the visual analog scale (VAS) and tenderness by the knee subscale of the RAI. The Western
Ontario Mc Master scale (WOMAC) was recorded and the Kellgren–Lawrence grading used to
assess radiographic severity. The synovial level of VEGF was assessed using ELISA.
Results: The mean age was 56.15 ± 7.77 years and body mass index 28.1 ± 4.04. All patients
had knee effusion; 40% were bilateral and 60% unilateral. The mean duration of knee pain was
3.01 ± 1.43 years; duration of morning stiffness was 15.75 ± 3.72 min. The mean WOMAC was
44.22 ± 11.46 and modiﬁed RAI 5.45 ± 2.94. The mean knee subscale of RAI was 2.9 ± 1.16
and VAS for knee pain 5.7 ± 2.92. The mean synovial VEGF level was 693.71 ± 314.63 pg/ml.
There was a signiﬁcant increase in the synovial VEGF compared to the reference value
(p= 0.0001). There was a signiﬁcant correlation between the synovial VEGF and patients’ age
(p= 0.04), knee pain duration (p= 0.025), morning stiffness (p< 0.0001), modiﬁed RAI
(p= 0.0001), knee subscale of RAI (p< 0.0001), VAS for knee pain (p< 0.0001) and WOMAC
(p= 0.0001). There was a signiﬁcant negative correlation between synovial VEGF and muscle
30 A. Gaballah et al.strength grading (p= 0.0001) and a signiﬁcant correlation with the radiological assessment
(p= 0.0001).
Conclusion: Synovial VEGF signiﬁcantly correlated with clinical manifestations, functional
impact, as well as radiological changes of KOA.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Osteoarthritis (OA) refers to failure of the joint accompanied
by varying degree of joint pain, functional limitation and
reduced quality of life [1]. Osteoarthritis is a disease with many
associated comorbidities. In a study on Egyptian patients with
primary OA, a higher risk of subclinical atherosclerosis was
detected [2].
In a cohort of 180 Egyptian patients with knee osteoarthri-
tis, joint pain and stiffness were the main symptoms and the
visual analog scale (VAS) of knee pain ranged between 30
and 85%. They had functional impairment as assessed by the
Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC). All the included patients were suffering
from knee cartilage degradation on radiological assessment
ranging between 2 and 3 as assessed by the Kellgren and
Lawrence severity scale [3]. In another study on 20 patients
with knee OA, 70% of patients had moderate OA (grade 2)
and 30% had minimal OA (grade 1), according to the same
scale [4].
Many factors have been implicated in the pathogenesis of
OA. Osteopontin, a potential inﬂammatory cytokine, was esti-
mated in Egyptian patients with knee OA and the synovial ﬂu-
id level was found to be signiﬁcantly higher than in the plasma
level of the control and signiﬁcantly correlated with the sever-
ity of knee pain [5,6]. Its synovial ﬂuid levels also correlated
with disease severity assessed according to the Kellgren–Lawr-
ence grading [5]. Oxidative stress has also been implicated in
the pathogenesis of OA [7]. The serum cartilage oligomeric
matrix protein (COMP) level was also found to be an impor-
tant marker of disease activity and cartilage destruction in
knee OA patients [8]. The measurements of both hyaluronic
acid and COMP were found to be of diagnostic and prognostic
value in differentiating knee OA patients with early joint
destruction. In combination with other biochemical markers
as well as with the clinical and radiographic features, the clin-
ical assessment of patients would remarkably improve [9].
Numerous studies have shown that inﬂammatory proangio-
genic cytokines such as vascular endothelial growth factors
(VEGFs) have been implicated in the pathogenesis of OA
[10]. Inﬂammation can stimulate angiogenesis and angio-
genesis can facilitate inﬂammation. Inﬂammatory cells such
as macrophages that are present abundantly in chronically
inﬂamed osteoarthritic synovium produce inﬂammatory med-
iators that induce angiogenesis in vivo. Inﬂammation results
in hypoxia. Tissue hypoxia is a potent stimulator of angio-
genesis. Angiogenesis through angiogenic factors such as
VEGF facilitate plasma extravasation and inﬂammatory cell
recruitment. Angiogenesis at osteochondral junction leads to
endochondral ossiﬁcation and the formation of osteophytes.
Angiogenesis and joint damage further exacerbate inﬂamma-
tion. The newly formed vessel may become innervated andcould be a source of pain. Through these mechanisms angio-
genesis and inﬂammation can contribute to pain and joint
damage in OA [11].
The aim of the present study was to assess the synovial ﬂuid
vascular endothelial growth factor (VEGF) levels in knee
osteoarthritis (KOA) patients and correlate them with the clin-
ical, functional and radiological ﬁndings.
2. Patients and methods
The following data were recorded for all included patients
after they signed informed consent for inclusion into the
study: Demographic data, weight and height to calculate
body mass index (BMI) [12,13], history of knee(s) pain (Site
of pain (right, left or bilateral), disease duration, relieving
and aggravating factors, associated morning stiffness (in
minutes), joint swelling, other joints involvement.). All
patients had musculoskeletal examination including detailed
knee joint examination [14], quadriceps muscle strength
grading by Medical research council (MRC) [15], degree of
tenderness assessed according to modiﬁed Ritchie articular
index (RAI) and RAI sub-scale for both knees [16], visual
analog scale (VAS) for knee pain was assessed [17] and
the Western Ontario and Mc Master Universities
(WOMAC) index score for detection of the functional capa-
city of lower limbs was calculated [18,19]. Radiological
assessment with plain X-ray of both knees antero-posterior
and lateral standing views were done and Kellgren and
Lawrence grading criteria were used for assessment of radio-
graphic severity of knee OA [20].
Synovial VEGF levels for patients were assessed using
Enzyme-Linked ImmunoSorbent assay (ELISA). The refer-
ence value for synovial VEGF was taken after Fay et al.
[21]. In their study collected synovial ﬂuid from healthy joints
of deceased donors (n= 5) was assayed by Enzyme-Linked
ImmunoSorbent assay (ELISA) and the median VEGF level
in healthy synovial ﬂuid was 36 pg/ml [21]. The study was
approved by the local university ethics committee and the
study conforms to the provisions of the Declaration of
Helsinki in 1995. All patients gave their informed consent prior
to their inclusion in the study.
Statistical analysis: The data were analyzed statistically
using the SPSS-17 (Statistical Package for Social Science ver-
sion 17). Means and standard deviation were used to describe
data distribution. Analysis of Variance (ANOVA or F-test) is
used for comparison of more than 2 means. Least signiﬁcant
difference (LSD) is basically a t-test, used only when F value
is signiﬁcant to detect the presence of signiﬁcance between each
2 groups. Spearman (nonparametric) rank correlation (rs) test
was used to test correlation between 2 quantitative variables.
The test was considered signiﬁcant if the probability (p-value)
was less than 0.05.
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Twenty patients suffering from primary knee OA were
included in this study. They were eight males (40%) and twelve
females (60%). The mean age of patients was
56.15 ± 7.77 years (ranged from 40 to 67). Five patients had
normal weight (25%), eight were overweight (40%) and seven
obese (35%); their mean BMI was 28.1 ± 4.04 (ranged from
20 to 31). Table 1 shows clinical, functional and laboratory
disease characteristics of the patients. All patients had knee
effusion, twelve had unilateral (60%) and eight had bilateral
knee effusion (40%). Eight patients had unilateral ﬂexion
deformity (40%). Fifteen patients suffered from generalized
OA (75%) where other joints were affected such as DIPs, lum-
bar and cervical vertebrae while only ﬁve patients suffered
from just knee(s) OA (25%).Table 2 Comparison between primary knee osteoarthritis patients s
value.
KOA patients (n= 20)
VEGF synovial (pg/ml)
Range 232–1151
Mean ± SD 693.7 ± 314.6
KOA: knee osteoarthritis, VEGF: vascular endothelial growth factor.
Table 1 Clinical and functional characteristics and synovial vascula
with primary knee osteoarthritis.
Clinical characteristics Minimum
Duration of knee pain (years) 0.25
Duration of MS (minutes) 10
VAS for knee pain 2
Knee tenderness# 1
Modiﬁed RAI score 1
WOMAC index score 24
Synovial level of VEGF (pg/ml) 232
MS=morning stiffness, WOMAC=Western Ontario and McMaster U
RAI = Ritchie articular index, VEGF= vascular endothelial growth fac
# Knee tenderness assessed using knee sub-scale of modiﬁed RAI.
Table 3 Comparison of the synovial ﬂuid vascular endothelial gro
radiological gradings in patients with primary knee osteoarthritis.
Parameter Synovial VEGF in KOA patient
Mean ± SD
Muscle grading
Grade 3 1008.1 ± 209.2
Grade 4 551.5 ± 223.6
Grade 5 375.7 ± 39.7
Radiological grading
Grade 1 375.7 ± 39.7
Grade 2 447.6 ± 208.6
Grade 3 733.3 ± 101.6
Grade 4 1008.1 ± 209.2
VEGF= vascular endothelial growth factor.Table 2 shows comparison between patients and the refer-
ence value regarding the synovial VEGF levels. There was a
statistically signiﬁcant increase in the synovial VEGF in
patients (t= 14.16, p= 0.0001). Table 3 shows the compar-
ison between synovial VEGF levels among different muscle
strength grading groups and radiological grading in the stud-
ied patients. A statistically signiﬁcant increase of synovial
VEGF level was present in those with a decreased quadriceps
muscle strength grade compared to those with higher strength
grades (p< 0.01). A statistically signiﬁcant increase of syn-
ovial VEGF level was present with the increased radiological
grading (p< 0.01).
There was a signiﬁcant correlation between synovial VEGF
and patient age (r= 0.46, p= 0.04). Whereas, there was no
signiﬁcant correlation between synovial VEGF and BMI
(r= 0.14, p= 0.56). Table 4 shows a signiﬁcant correlationynovial vascular endothelial growth factor (VEGF) and reference
Reference value t (p)
16–92 14.2 (0.0001)
36.0 ± 19.14
r endothelial growth factor (VEGF) among the studied patients
Maximum Mean ± SD
5 3.01 ± 1.43
20 15.75 ± 3.73
10 5.70 ± 2.92
5 2.90 ± 1.17
11 5.45 ± 2.95
62 44.22 ± 11.46
1151 693.71 ± 314.63
niversities Osteoarthritis Index, VAS = visual analog scale for pain,
tor.










Table 4 Correlations between synovial vascular endothelial
growth factor (VEGF) level and clinical and functional
manifestations of the studied patients with primary knee
osteoarthritis.
Clinical manifestations of the knee Synovial VEGF r (p)
Duration of knee pain (years) 0.5 (0.025)
Morning stiﬀness duration (minutes) 0.82 (<0.0001)
Tenderness by modiﬁed RAI 0.81 (0.0001)
Sub-scale of RAI for knee tenderness 0.73 (<0.0001)
VAS for knee pain 0.84 (<0.0001)
WOMAC index score 0.96 (0.0001)
WOMAC=Western Ontario and McMaster Universities
Osteoarthritis Index, VAS = visual analog scale for pain,
RAI = Ritchie articular index, VEGF= vascular endothelial
growth factor. p< 0.05 = signiﬁcantly different.
Figure 1 Correlation between synovial ﬂuid vascular endothelial
growth factor (VEGF) level and muscle strength grading in
patients with primary knee osteoarthritis.
Figure 2 Correlation between synovial ﬂuid VEGF level and
radiological assessment in patients with primary knee
osteoarthritis.
32 A. Gaballah et al.between the synovial VEGF level and the studied clinical and
functional manifestations of the patients. There was a
signiﬁcant negative correlation between VEGF in synovial
ﬂuid and muscle strength grading (p< 0.01) (Fig. 1). Therewas a statistically signiﬁcant positive correlation between syn-
ovial VEGF and radiological assessment (p< 0.01) (Fig. 2).
4. Discussion
The current study was carried out on 20 knee OA patients to
highlight the role of VEGF in knee OA and its correlation with
some variables which determine OA severity such as WOMAC
index score for functional assessment, radiological assessment,
degree of tenderness by RAI, VAS for pain assessment, dura-
tion of knee pain and morning stiffness.
In the current study, synovial ﬂuid VEGF was signiﬁcantly
higher in OA patients compared to the reference value. This is
according to Fay et al. [21] who found that the level of VEGF
in synovial ﬂuid from patients suffering from OA is 60-fold
higher than healthy joints. They explained their results on
the basis that inﬂammation in OA is known to be associated
with activation of host angiogenesis where VEGF is one of
the most potent proangiogenic stimuli of neovascularization
[21,22].
In the current study, there was a signiﬁcant correlation
between synovial ﬂuid level of VEGF and OA radiological
grading. These results were in agreement with Ru¨benhagen
et al. [23] and Klaus et al. [24]. Ru¨benhagen et al. [23] found
that VEGF level in synovial ﬂuid was correlated with radiolo-
gical grading as assessed by Kellgren and Lawrence. In their
study synovial ﬂuid obtained from 82 patients, who had under-
gone total knee replacement surgery, was assayed by ELISA.
Moreover, Klaus et al. [24] found a signiﬁcant correlation
between VEGF level in synovial ﬂuid and radiographic dam-
age of knee OA according to Ahlbaeck score. In contrast to
this result with radiological grading, Anitua et al. [25] found
no signiﬁcant association between radiographic grading
(Ahlba¨ck grading) and the levels of potential biomarkers in
synovial ﬂuid, including VEGF. This may be due to the
different types of OA radiological scales and/or methods of
statistical analysis used.
In the current study there was a signiﬁcant correlation
between synovial VEGF and VAS for pain assessment, the
degree of tenderness as assessed by the modiﬁed Ritchie articu-
lar index and its subscale for knee tenderness. Pain and inﬂam-
mation are often associated with increased tenderness. In this
context VEGF acts as a pro-inﬂammatory cytokine by induc-
ing adhesion molecules that bind leukocytes to endothelial
cells, an initial and essential step toward inﬂammation [26].
Moreover, main events occurring in the cartilage during the
pathogenesis of OA include an imbalance of metabolic and
degradation signals, driven by cytokine cascades and the pro-
duction of inﬂammatory mediators [27,28]. The close interde-
pendence of angiogenesis and inﬂammation is often
highlighted by angiogenic factors such as VEGF [29]. There
are no previous studies which correlate between measured syn-
ovial ﬂuid level of VEGF and degree of tenderness in patients
with primary knee OA.
In the current study, there was an increase in synovial ﬂuid
VEGF level with decreasing quadriceps muscle strength grad-
ing. An important determinant of weakness in knee OA is
arthrogenic muscle inhibition (AMI) – an ongoing neural inhi-
bition that prevents the quadriceps muscles from being fully
activated [30–32]. Being a direct cause of quadriceps weakness,
AMI may contribute to muscle atrophy [32] and, in more
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[33–35]. There is evidence suggesting that AMI is caused by
a change in the discharge of sensory receptors from the dam-
aged knee joint [32,35,36]. In turn, a change in afferent dis-
charge may alter the excitability of multiple spinal reﬂex and
supra spinal pathways that combine to limit activation of the
quadriceps a-mono neuron pool [32]. An increase in knee joint
mechanoreceptor and/or nociceptor discharge (as with acute
swelling, pain or inﬂammation) leads to marked quadriceps
AMI [37–39]. Therefore it can be assumed that increased syn-
ovial ﬂuid level of VEGF (which was associated with increased
joint pain and tenderness in the current study and hence
inﬂammation) may indirectly (among other factors) account
for decreased quadriceps muscle strength among the studied
patients. There are no previous studies which correlate between
measured synovial ﬂuid level of VEGF and quadriceps muscle
strength grading in patients with primary knee OA.
In the current study WOMAC score for functional assess-
ment was increased with increasing synovial ﬂuid level of
VEGF. This implies that increased functional impairment can
be aggravated by increasing OA severity as reﬂected by radiolo-
gical grading, synovial inﬂammation and pain. There are no
previous studies which correlate between measured synovial
ﬂuid level of VEGF and functional capacity in patients with
primary knee OA as assessed by WOMAC index score.
In the present study there was a signiﬁcant correlation
between synovial ﬂuid level of VEGF and patients, age. This
was in agreement with Ru¨benhagen et al. [23].
In the current work, there was no signiﬁcant correlation
between synovial ﬂuid level of VEGF and BMI. Obesity is an
important aggravating factor for OA progression, but there
are multiple factors other than obesity affecting the progression
of OA such as aging, genetic factors, occupation, thigh muscle
weakness and patients’ life style [40]. In addition, the small sam-
ple size could also contribute to this result. There are no previ-
ous studies which correlate between measured synovial ﬂuid
level of VEGF and BMI of patients with primary KOA.
According to the present study results, it can be assumed
that knee OA severity for studied patients was associated with
synovial VEGF. This comes in accordance with Pfander et al.
[41] who stated that the number of VEGF positive chondro-
cytes in cartilage samples correlates with OA severity, suggest-
ing that ingrowing blood vessels may liberate pro-apoptotic
signals in articular cartilage leading to apoptotic events in
OA chondrocytes. In their study, OA severity was determined
according to histochemical grading and 20 severe OA human
cartilage samples were obtained from patients who had under-
gone total knee replacement, then specimens were prepared
and scored according to Mankin histological scoring. The
results of the present study were also in agreement with
Tibesku et al. [42], who demonstrated that VEGF is synthe-
sized by chondrocytes of the articular cartilage in knees of
healthy rabbits after induction of OA because of anterior cru-
ciate ligament (ACL) resection and signiﬁcantly correlated
with the degree of osteoarthritis.
In conclusion, synovial VEGF signiﬁcantly correlated
with clinical manifestations, functional impact, as well as
radiological changes of knee osteoarthritis. A deeper under-
standing of the effects of biochemical parameters including
VEGF on the initiation and progression of arthritic diseaseswill help us to ﬁnd therapeutic targets to prevent and treat
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